Johnson and Johnson Near Record High Still Offers a Buy Case on Pipeline Depth and Defensive Yield
Johnson and Johnson’s diversified pharmaceutical portfolio and MedTech segment support the bull case even as the stock trades near record highs, with pipeline catalysts in oncology set to extend the thesis.
Key points
- J&J near record highs with analysts citing pipeline depth in oncology and immunology as bull case
- Post-Kenvue spinoff positions J&J as pure-play pharma with AA+ credit and consistent dividends
- Key watch: Q3 earnings pipeline readouts and FDA Medicare drug pricing negotiation scope
Does this change your view on the stock? Share your take below.
Read the full analysis on market.news
🇺🇸 United States Stocks Earnings healthcare pharma dividends analyst-upgrade